

**Serious Adverse Event Reporting**
**ANRS 12249 Initial SAE Notification**

Completed forms must be sent to  
ANRS within 48 hrs.  
Email: [pharmacovigilance@anrs.fr](mailto:pharmacovigilance@anrs.fr)  
Fax: +33 153 946 002



00317402

SAE No.

SAE Visit Date

20150420

Initial Notification Date

20150422

Notification time

1600

**1. Patient details**

TasP ID

19804

Name

M.B.

Sex

☒ Male

☐ Female

Date of birth

29430212

Enrolment date

20130312

**2. Measurements**

Height

165 cms

Last known: Weight

56

Weight Date

20150312

CD4 count

379

CD4 Date


20150208

Viral Load

44

Viral Load Date

20150218


**3. By which criteria is this adverse event considered to be "Serious"?**

Tick all that apply

- ☒ Resulted in death → Date of death 20150406 Probable cause Suspected Prostate Cancer
- ☐ Life threatening (i.e. at risk of death at time of event)
- ☐ Caused or prolonged hospitalisation (not elective hospitalisation for a pre-existing condition)
- ☐ Persistent or significant disability / incapacity
- ☐ Congenital abnormality / birth defect
- ☐ Grade 4 clinical and biological events
- ☐ Other serious, medically-important condition → Specify

**4. Details of SAE**

Enter each adverse event (e.g. symptom, sign, syndrome or diagnosis) on a separate line

Event Name
Date investigator became aware
Date of onset of SAE

1. Death possibly 2° Prostate Cancer 20150420 20150406

2.

3.

4.

5.

**5. Description of SAE**

Include details of body site, relevant laboratory tests, treatments received and relevant medical history.

Attach copies of any relevant hospital records, laboratory test results etc.

Participant on Lamivudine, Zidovudine, Efavirenz with CD4 count 314 and viral load 44. He was seen by trial clinician on 18/2/15 with difficulty passing urine. He was investigated for prostate cancer; started on Cardura XL and referred to urology outpatients. He was for review at urology on 30/4/2015. He died at home (died in his sleep) as reported by relatives on 06/04/2015.

## 6. Medications

List all drugs taken (or prescribed) before occurrence of SAE

Generic Name	Daily dose	Route of administration	Indication	Date started	Date stopped	Causality assessment	Expected reaction? (BNF/SPC)	Action taken
1. Lamivudine	300mg	oral	HIV	20131018		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
2. Zidovudine	300mg	oral	HIV	20131018		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
3. Efavirenz	600mg	oral	HIV	20131018		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
4. Doxazosin	4mg	oral	Prostate Ca	20150218		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
5.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
6.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop

## 7. Other causes of SAE, if unrelated to drugs mentioned in Section 6 above

7a. According to the physician, is this SAE likely to be related to participation in the research?

Yes ☐ No ☒

7b. According to the physician, is this SAE related to any causes other than the research?

This includes the patient's medical history

☒ Yes

☐ No

Describe

Patient most likely had prostate cancer. PSA was 57 and patient was lymphatic.

## 8. SAE Outcome

☒ Died

Unknown to date

Ongoing

Improved

Recovered

→ A complementary SAE notification must be submitted within 8 days

→ Date of recovery

Recovered without sequelae

or

Recovered with sequelae

→ Describe

## Physician reporting SAE

Name DR GUG'ELHLE WIKHULISI

Signature

Date form completed 20150422